'Milestones' in 200 Years of Parkinson's Research

Marking the 200th anniversary of the first published description by James Parkinson of the disease that would come to bear his name, the Journal of Parkinson’s Disease has published a special issue that features invited commentaries by those responsible for some of the greatest advances in understanding and treating Parkinson's.

From the shaking palsy to alpha-synuclein read the stories behind the science from many of the researchers who played key roles in reaching significant milestones:

The Journal of Parkinson's Disease - 200 years of research (IOS Press)

Latest

Celebrating Tom - an evening of tributes and triumphs.

On 12th September, we celebrated the life and achievements of the wonderful Tom Isaacs - co-founder of The Cure Parkinson's Trust. Tom's incredible legacy remains at the absolute heart of the Trust.
The 'Tom Isaacs Award'

The Van Andel Research Institute and The Cure Parkinson’s Trust will introduce 'The Tom Isaacs Award' to be presented at the annual Grand Challenges in Parkinson’s and Rallying to the Challenge meeting on 27th & 28th September in Grand Rapids, Michigan.
The Tom Isaacs Charity Golf Day, Denham Golf Club

Our annual fundraising golf day will be taking place on Thursday 19th October 2017 at Denham Golf Club, Buckinghamshire.
Major gifts

Celebrating Tom - an evening of tributes and triumphs.

On 12th September, we celebrated the life and achievements of the wonderful Tom Isaacs - co-founder of The Cure Parkinson's Trust. Tom's incredible legacy remains at the absolute heart of the Trust.
Alpha-synuclein oligomers: a new hope

A report part funded by The Cure Parkinson's Trust assesses the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discusses the advances in our understanding of the role of alpha-synuclein in Parkinson’s and current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.
The Association of Pesticide Use and Parkinson's

Researchers assessed the influence of occupational pesticide use on the prevalence of Parkinson's Disease in people with information available concerning occupational, residential, and household sources of pesticide exposure.
Breaking News: Diabetes Drug Shows Potential as Disease-Modifying Therapy for Parkinson’s

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Diabetes drug (Bydureon) Showed Potential as Disease-modifying Therapy for Parkinson's: More Research Needed

At a recent meeting, hosted by The Cure Parkinson's Trust, attendees discussed the impact of the recently published Bydureon trial, related research and the next steps needed for GLP-1 agonists in Parkinson's.
CPT Approves Funding for Two Pre-clinical Studies of Anti-diabetic Drugs

MSDC-0160 and Exendin-4 have shown potential to slow the progression of Parkinson's in pre-clinical work funded by CPT. Moving these drugs to trial is now crucial.
Reducing Inflammation in Parkinson's using a Clinically Approved Cancer Drug

Based on the wealth of evidence that inflammation plays a key role in diseases of the central nervous system, it is thought this line of treatment using a clinically approved cancer drug has significant potential to slow or stop disease progression in Parkinson's.
FDA Approval of Nilotinib in Collaboration Trial

The Cure Parkinson's Trust has collaborated with The Michael J Fox Foundation (MJFF) and the Van Andel Research Institute (VARI) of Grand Rapids, Michigan on the clinical development of nilotinib toward the launch of this clinical trial.
Tribute to Tom

Clare Balding and CPT's own Helen Matthews pay a wonderful tribute to Tom Isaacs on BBC Radio 4, Last Word.
Dogs to be Taught to Sniff Out Parkinson's

Dogs could soon be used to sniff out Parkinson’s disease years before symptoms start to show.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Trials - Repurposed drugs

Our Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop, or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Our story
Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic?

A research paper published in the Journal of Parkinson's Disease (Spring 2016) discusses an impending clinical trial in Parkinson's disease (PD) using parthenogenetic stem cells.
Apply for Funding
Breaking News: Diabetes Drug Shows Potential as Disease-Modifying Therapy for Parkinson’s

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
The NAC Trial - the facts
Study links Parkinson's disease to Gut Bacteria

A new study finds that people with Parkinson's disease appear to have distinctly different gut bacteria.